Patents by Inventor Björn Holm

Björn Holm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Persisted enterprise graph queries
    Patent number: 11947597
    Abstract: A computer search service can receive an enterprise graph query from a client computing device that is remote from the computer search service, with the enterprise graph query identifying an actor object set, a target object set, and a relationship between the actor object set and the target object set. The search service can return results of the enterprise graph query to the client device. The search service can receive from the client device an indication of user input instructing the search service to persist the enterprise graph query, with the indication of user input also instructing the search service to associate the persisted enterprise graph query with an entity. Moreover, in response to receiving the indication of user input, the search service can persist the enterprise graph query as well as associate the persisted enterprise graph query with the entity and/or enter a subscription entry for the query.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 2, 2024
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Fredrik Holm, Josh Stickler, Manfred Berry, Sveinar Rasmussen, Bjørn Olstad
  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20240101549
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 28, 2024
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG
  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20230312550
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 5, 2023
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG
  • MGluR5 modulators I
    Patent number: 7678796
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: March 16, 2010
    Assignee: AstraZeneca AB
    Inventors: Andreas Wallberg, Karolina Nilsson, Björn Holm, Mats Nagard, Kenneth Granberg, Abdelmalik Slassi, Louise Edwards, Methvin Isaac, Tao Xin, Tomislav Stefanac